NCT02565992View on ClinicalTrials.gov

Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 17, 2015

Primary Completion Date

November 4, 2019

Study Completion Date

November 4, 2019

Conditions
Melanoma
Interventions
BIOLOGICAL

CAVATAK

Maximum dose of CVA21 is 3 x 10E+08 TCID50 (about 4.5 x 10E+06 TCID50/kg for a 70-kg patient) by intratumoral administration.

DRUG

Pembrolizumab

Intravenous pembrolizumab at 2 mg/kg solution.

Trial Locations (3)

44718

Gabrail Cancer Center Research, Canton

90404

John Wayne Cancer Institute, Santa Monica

08901

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors

Lead Sponsor

Viralytics
All Listed Sponsors
lead

Viralytics

INDUSTRY

NCT02565992 - Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA) | Biotech Hunter | Biotech Hunter